Eficacia y seguridad de la combinación metotrexate leflunomida en una cohorte colombiana de pacientes con artritis reumatoide: estudio multicéntrico

Cubides Acosta, María Fernanda

dc.contributor.advisor	Londoño Patiño, John Darío
dc.contributor.advisor	Granados, Carlos Eduardo
dc.contributor.author	Cubides Acosta, María Fernanda
dc.date.accessioned	2012-02-07T19:26:17Z
dc.date.available	2012-02-07T19:26:17Z
dc.date.issued	2012-02-07
dc.identifier.citation	Latin American Rheumatology Associations of the PanAmerican League of Associations for Rheumatology (PANLAR) Grupo Latinoamericano de Estudio de Artritis Reumatoide (GLADAR) First Latin American position paper on the pharmacological treatment of rheumatoid arthritis Rheumatology. 2006;45:7–22
dc.identifier.citation	Grupo de Expertos de la Asociación Colombiana de Reumatología, Primer Consenso Colombiano Sobre el tratamiento de la Artritis Reumatoide Temprana, Rev Colomb Reumatol. 2002; 9 323- 331
dc.identifier.citation	Mora C, Díaz J, Quintana G. Costos directos de la artritis reumatoide temprana en el primer año de atención: simulación de tres situaciones clínicas en un hospital universitario de tercer nivel en Colombia. Biomedica. 2009;29:43-50.
dc.identifier.citation	Cardiel MH. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology 2006, 45 Suppl 2:7-22
dc.identifier.citation	Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors.[Abstract] Ann Intern Med. 1980; 93:551–6.
dc.identifier.citation	Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum. 2003;48:46–53
dc.identifier.citation	Anaya JM , Correa PA, Mantilla RD , Jimenez F , Kuffner T , McNicholl JM Rheumatoid arthritis in African Colombians from Quibdo. Semin Arthritis Rheum. 2001 31:191-8
dc.identifier.citation	Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 31:315-24
dc.identifier.citation	Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993; 36:729-40.
dc.identifier.citation	Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D. How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol. 1993; 11:117-21.
dc.identifier.citation	Prevoo ML, Vant Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty eight joint counts . Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis . Arthritis Rheum 1995; 38: 44 -8
dc.identifier.citation	Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Crossvalidation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998; 51:1171-8
dc.identifier.citation	O'DeU JR, Haire CE, Erikson N, Dtymalski W, Palmer W, Eckhoff PJ, etal. Treatment of rheumatoid arthritis with methotrexate alone, sulphasalazine and hydroxychloroquine, or a combination of all three medications. N EngI J Med.1996;334:1287-91.
dc.identifier.citation	Fox Rl, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol.1999;93:198-208.
dc.identifier.citation	Strand V, Cohen S, Schif FM, Weaver A, Fleischmann R, Cannon G, et al.Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999; 159:2542-50
dc.identifier.citation	Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in naive rheumatoid arthritis: a double-blind, randomised, multicenter trial. European Leflunomide Study Group. Lancet. 1999;353 :259-66.
dc.identifier.citation	Weinblatt ME, Kremer JM, Coblyn JS, Maier AL,Helfgott SM, Morrell M, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 1999;42:1322-8.
dc.identifier.citation	S-S Lee, Y-W Park, JJ Park, YM Kang, EJ Nam, SI Kim, JH Lee, W-H Yoo, Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis Scand J Rheumatol 2009;38:11–14
dc.identifier.citation	Vibeke Strand; Stanley Cohen,Michael Schiff, Arthur Weaver, Roy Fleischmann;Grant Cannon, Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate, Arch Intern Med. 1999.159 : 2543-50
dc.identifier.citation	Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:726–33.
dc.identifier.citation	Furst D, Luggen M, Thompson A, Coleman J. Adding leflunomide to patients with active rheumatoid arthritis while receiving methotrexate improves physical function and health-related quality of life [abstract]. Arthritis Rheum 2000;43 Suppl:344
dc.identifier.citation	Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137–41.
dc.identifier.citation	Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043–9.
dc.identifier.citation	Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951–60
dc.identifier.citation	Van Riel P. Leflunomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate. Clin Exp Rheumatol 2003;21:695–6.
dc.identifier.citation	Antony T, Jose VM, Paul BJ, Thomas T. Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Indian J Med Sci. 2006;60:318-26.
dc.identifier.citation	Willkens RF, Urowitz MB, Stablein DM, McKendry RJR Jr, Berger RG, Box JH, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:849–56
dc.identifier.citation	Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:259–69.
dc.identifier.citation	Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003;30: 1182–90.
dc.identifier.uri	http://hdl.handle.net/10818/1231
dc.description.abstract	La combinación metotrexade -leflunoamida es eficaz en el tratamiento de la artritis reumatoide (AR) aunque su seguridad ha sido cuestionada. Objetivos: Evaluar la eficacia y seguridad de la combinación metotrexate – leflunoamida en el tratamiento de pacientes con AR que han fallado a la terapia convencional. Métodos: Estudio 2 semanas que incluyo 88 pacientes, se evaluó la actividad de la enfermedad mediante: Respuesta ACR, DAS 28, HAQ para la capacidad funcional y SF12 para la calidad de vida. La seguridad se evaluó mediante el registro de eventos adversos y resultados de laboratorio. Resultados: 72(82%) pacientes completaron el estudio. Hubo mejoría significativa de la enfermedad. Se presentaron 30 eventos adversos. Conclusiones: la combinación de metotrexate-leuflonoamida es efectiva pero se requiere control estricto.	es_CO
dc.language.iso	spa	es_CO
dc.subject	Artritis reumatoide -- Investigaciones -- Colombia	es_CO
dc.subject	Artritis reumatoide -- Enfermedades -- Colombia
dc.subject	Artritis -- Tratamiento -- Colombia
dc.title	Eficacia y seguridad de la combinación metotrexate leflunomida en una cohorte colombiana de pacientes con artritis reumatoide: estudio multicéntrico	es_CO